FIELD: medicine; oncology.
SUBSTANCE: method involves introduction of dendritic cells (DC) induced in vitro to start aging and characterised with the ability to grasp and process antigene in vivo. Pharmaceutical composition under the invention contains these DC combined with pharmaceutically acceptable introduction carrier.
EFFECT: induction of antitumor immune response.
32 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS RELATED TO ACTIVATED DENDRITIC CELLS COMPOSITIONS AND TO IMMUNOTHERAPEUTIC TREATMENT OF INDIVIDUALS WITH ADVANCED CANCER | 2016 |
|
RU2749610C2 |
| DENDRITIC CELL GENERATION FROM MONOCYTIC DENDRITIC CELL PRE-CURSORS BY MEANS OF GM-CSF IN ABSENCE OF ADDITIONAL CYTOKINES | 2004 |
|
RU2364625C2 |
| SYSTEM AND METHOD OF OBTAINING AND STORAGE OF ACTIVATED MATURE DENDRITIC CELLS | 2011 |
|
RU2575978C2 |
| METHOD OF ANTITUMOUR IMMUNOTHERAPY | 2012 |
|
RU2530523C2 |
| IMPROVED COMPOSITION FOR INHIBITION OF TUMOUR CELL PROLIFERATION | 2011 |
|
RU2565542C2 |
| COMPOSITIONS AND METHODS FOR PRODUCING T-CELLS | 2018 |
|
RU2793344C2 |
| CO-DIFFERENTIATION OF MONOCYTES FROM ALLOGENEIC DONORS | 2013 |
|
RU2668816C2 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| CELL PRODUCT FOR LOADING AND ACTIVATION OF HUMAN DENDRITE CELLS | 2019 |
|
RU2714208C1 |
